Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of human cancer cell lines treated with the histone deacetylase inhibitor romidepsin

ABSTRACT: Global gene expression analysis was performed on 8 cancer cell lines after treatment with romidepsin for 6h, or 6h treatment followed by 12 h incubation with drug free medium. The cell lines were selected based on their response spectrum to romidepsin, and included HUT78, LOXIMVI, M14, A549, MDA231, ACHN, MiaPaca2 and PC3. Differentially expressed genes (DEG) included genes involved in DNA damage repair (DDR) pathways. The Affymetrix Human Genome U133 Plus 2.0 platform was used for the gene expression profiling.

ORGANISM(S): Homo sapiens

PROVIDER: GSE133120 | GEO | 2021/04/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Comparison between HuT78 parental and romidpepsin-selected cell lines

Project description:Gene expression values were determined for HuT78 parental cells and cells selected with romidpesin in the presence of P-glycoprotein inhibitors. HuT78 DpVp35 cells are maintained in 35 ng/ml romidepsin with 2.5 µg/ml verapamil and HuT78 DpP100 cells are maintained in 100 ng/ml romidepsin with 1 µM valspodar To identify molecular determinants of histone deacetylase inhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin in the presence of P-glycoprotein (Pgp) inhibitors to prevent transporter upregulation. Resistant sublines were 250- to 385-fold resistant to romidepsin and were resistant to apoptosis induced by apicidin, entinostat, panobinostat, belinostat and vorinostat. A custom Taqman array identified increased insulin receptor (INSR) gene expression; immunoblot analysis confirmed increased expression and a 4- to 8-fold increase in mitogen activated protein kinase (MAPK) kinase (MEK) phosphorylation in resistant cells compared to parental cells. Resistant cells were exquisitely sensitive to MEK inhibitors and apoptosis correlated with restoration of proapoptotic Bim. Romidepsin combined with MEK inhibitors yielded greater apoptosis in cells expressing mutant KRAS compared to romidepsin treatment alone. Gene expression analysis of samples obtained from patients with CTCL enrolled on the NCI1312 Phase II study of romidepsin in T-cell lymphoma suggested perturbation of the MAPK pathway by romidepsin. Immunohistochemical analysis of Bim expression demonstrated decreased expression in some skin biopsies at disease progression. These findings implicate increased activation of MEK and decreased Bim expression as a resistance mechanism to HDIs, supporting combination of romidepsin with MEK inhibitors in clinical trials. Gene expression in resistant lines was compared to parental lines

2013-03-12 | E-GEOD-45018 | biostudies-arrayexpress

Quantitative RNAseq Analysis of Treatment Outcomes with Talazoparib, Romidepsin or Combination in MBL2 cell line

Project description:To explore the molecular mechanisms by which romidepsin potentiates the effect of talazoparib, RNA sequencing analysis of MBL2 cell lines treated with talazoparib, romidepsin, or talazoparib plus romidepsin was performed. 40% of the 2023 genes in combination were from talazoparib, whereas only 5.9% of the genes deregulated during the treatment with the combination of talazoparib plus romidepsin were from the effect of romidepsin. 94 genes were presented in all three treatment groups and included upregulation of Prdm1, Dusp5, and CD74, among others. Analysis of genes responsible for DNA repair, cell cycle arrest and apoptosis demonstrated the contribution of romidepsin to downregulation of DNA repair, the synergistic effect of romidepsin and talazoparib on downregulation of genes of cell cycle leading to cell cycle arrest, and activation of apoptosis by talazoparib predominantly.

2020-09-04 | GSE157434 | GEO

Comparison between HuT78 parental and romidpepsin-selected cell lines

2013-03-12 | GSE45018 | GEO

Expression data of Panc1 cells treated with romidepsin and tamoxifen

Project description:Tamoxifen enhances romidepsin-induced senescence in pancreatic cancer cells. We compared gene-expression profile among untreated control, romidepsin-treated, tamoxifen-treated, and romidepsin plus tamoxifen-treated Panc1 cells.

2021-08-21 | GSE182526 | GEO

Expression data of MOLT-4 cells treated with romidepsin and tamoxifen

Project description:Tamoxifen enhaces romidepsin-induced apoptosis in T-cell malignant cells. We compared gene-expression profile among untreated control, romidepsin-treted,

2020-02-21 | GSE145606 | GEO

ChIP-seq. analysis of pan-histone 3 acetylation in Romidepsin treated TCam-2

Project description:ChIP-seq. analysis of TCam-2 16 h after 10 nanomolar Romidepsin application. DMSO treated cells were used as controls. For ChIP, an antibody against histone H3 pan-acetylation was used. These data are part of the article 'The Histone Deacetylase Inhibitor Romidepsin Efficiently Targets Cisplatin-resistant Germ Cell Cancer Cells via Downregulation of the SWI/SNF-Complex Member ARID1A' (Nettersheim et al., 2016). TCam-2 cells treated for 16h with romidepsin or the solvent were fixed by formaldehyde solution and further processed by Active Motif, including DNA shearing by sonication, chromatin-immunoprecipitaion, library generation and sequencing (NextSeq 500, Illumina). Pooled input DNA of each sample including spike-in Drosophila DNA was used as controls and for normalization. The 75-nt sequence reads were mapped against the genome using BWA algorithm. Duplicate reads were removed. Only peaks that align with no more than 2 mismatches and map uniquely to the genome were used for further analysis. Intervals / peaks were identified by the MACS peak finding algorithm (cutoff p-value 1x10-7) including ENCODE blacklist filtering

2016-09-01 | E-GEOD-78262 | biostudies-arrayexpress

Effect of Romidepsin treatment on patient-derived liver cancer cells

Project description:Romidepsin displayed potent antitumor activity in our lenvatinib-resistant PDCs, we wanted to investigate the underlying mechanism of how romidepsin initiated susceptibility to conquer lenvatinib resistance in liver cancer.

2024-03-17 | GSE227751 | GEO

Epigenetic inhibitors

Project description:The project aims to looks at differential gene targets in the human Sezary syndrome HuT78 cell line when treated with epigenetic inhibitors romidepsin, F5446, and chaetocin compared to the vehicle treated cells (DMSO) for 72hrs.

2022-10-26 | GSE159963 | GEO

RNA sequencing of BM-derived senescent MDSCs treated or not with Romidepsin

Project description:RNA sequencing of BM-derived senescent MDSCs treated or not with Romidepsin

2023-03-02 | GSE199921 | GEO

Nascent RNA sequencing (PRO-seq) after 200nM romidepsin treatment of H9 cells

Project description:Nascent RNA sequencing (PRO-seq) after 200nM romidepsin treatment of H9 cells

2019-12-12 | GSE141843 | GEO